Oticon Medical

Oticon Medical emerged within the Demant Group as a business dedicated to implantable hearing technology. It was distinct from Oticon's conventional hearing-aid operation, although the two businesses shared the wider Demant corporate family and the Oticon name. The company released its first products in 2009, entering a specialist field in which treatment involves implanted hardware, external processors, surgery, audiological fitting, and extended rehabilitation. The company's best-known line was Ponto, a bone-conduction implant system. Bone-conduction technology bypasses portions of the outer and middle ear by conveying sound vibrations through the skull to the cochlea. This approach can be clinically useful for selected people with conductive or mixed hearing loss and for some patients with single-sided deafness. Ponto developed through multiple generations, and the available reference material identifies the platform as having reached a fifth generation. Oticon Medical expanded its technological scope in 2013 by acquiring Neurelec, a French cochlear-implant producer. Cochlear implants differ from bone-conduction systems because they convert sound into electrical stimulation delivered to the auditory nerve through an implanted electrode array. The acquisition gave Oticon Medical a presence in another major segment of the hearing-implant market and added a product-development and manufacturing capability based on Neurelec's technology. The business was supported by an international specialist network rather than a mass consumer retail model. Its relevant stakeholders included ear, nose and throat surgeons, implant centers, audiologists, rehabilitation teams, caregivers, and patients. The supplied references do not provide enough detail to reconstruct the company's full manufacturing footprint, revenue history, executive roster, or market-by-market distribution structure. A major strategic change came in April 2022, when Demant announced that it had agreed to sell Oticon Medical to Cochlear Limited for DKK 850 million. Demant also announced that it would leave the hearing-implant business. The decision placed Oticon Medical's implant activities within the portfolio of a company specializing in cochlear and bone-conduction hearing implants, while allowing Demant to concentrate on its other hearing-care and diagnostic businesses. The available reference material does not establish all subsequent legal, operational, and branding changes, and therefore the current status of the Oticon Medical brand is left as unknown.

• 2022

  Agreement to sell the business to Cochlear

  [1]Oticonen.wikipedia.org

  Demant announced an agreement to sell Oticon Medical to Cochlear Limited for DKK 850 million and to withdraw from hearing implants.

• 2013

  Acquisition of Neurelec

  [1]Oticonen.wikipedia.org

  Oticon Medical acquired Neurelec, a French cochlear-implant manufacturer, expanding its portfolio into cochlear-implant technology.

• 2009

  First Oticon Medical products released

  [1]Oticonen.wikipedia.org

  Oticon Medical entered the hearing-implant market with its first products, operating as a sister business to Oticon within the Demant Group.

Specialist implantable hearing technology for patients who need alternatives to conventional hearing aids, with emphasis on bone-conduction solutions and cochlear implantation.

• Bone-conduction hearing implant

  Ponto

  Ponto is Oticon Medical's principal bone-conduction hearing-implant platform. It combines an implanted component with an external sound processor and is designed to transmit sound vibrations through the skull to the cochlea. The system is intended for appropriately selected patients with conductive or mixed hearing loss and for some people with single-sided deafness. The platform developed through successive generations and was identified in the reference material as reaching a fifth generation.

• Cochlear-implant system

  Neuro

  Neuro refers to the cochlear-implant product family associated with Oticon Medical after its expansion into cochlear implantation. Cochlear implants use an external processor and an implanted electrode system to convert sound into electrical stimulation for the auditory nerve. The business obtained its cochlear-implant capability through the 2013 acquisition of French manufacturer Neurelec.

• 2022

  Sell Oticon Medical to Cochlear and exit hearing implantsM&A

  Background

  Demant announced a strategic decision to withdraw from the hearing-implant business and focus on its other hearing-care activities.

  Action taken

  Demant agreed to sell Oticon Medical to Australian hearing-implant company Cochlear Limited for DKK 850 million.

  Aftermath

  The agreement transferred the Oticon Medical business toward a company whose core activities are hearing implants. The supplied references do not provide sufficient detail about the final legal structure or subsequent brand treatment.

  Agreed transaction value. DKK 850 million (April 2022 announcement)

  Source

• 2013

  Acquire Neurelec to expand into cochlear implantsM&A

  Background

  Oticon Medical had established itself in hearing implants, particularly bone-conduction technology, and sought a broader position in the implantable-hearing market.

  Action taken

  The company acquired Neurelec, a French producer of cochlear implants.

  Aftermath

  The acquisition added cochlear-implant technology and widened Oticon Medical's product scope beyond bone-conduction systems.

  Source

• 2020-09-25

  Oticon Medical launches Ponto Care app[3]Oticon Medical 推出 Ponto Care 应用hearinghealthmatters.org

  Reported: 2020-09-25

  Oticon Medical introduced the Ponto Care mobile application for bone-anchored hearing device users. The app adds an Aftercare section to the previously released Ponto Trial Companion app and includes tools for device care, implant-site tracking and recording hearing experiences.

1. 1Oticonen.wikipedia.org
2. 2Oticon Medical official websiteoticonmedical.com
3. 3Oticon Medical 推出 Ponto Care 应用hearinghealthmatters.org